drugset / Trial / NCT07855497
Efficacy and Safety of Second-Line Helicobacter Pylori Eradication
RandomizedParallel-groupOpen-labelTreatment
Summary
Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth).
Timeline
- Start
- 2021-02-01
- Primary completion
- 2026-09-28
- Completion
- 2027-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | 500 mg | — |
| Comparator | Amoxicillin | Other / unclassified | 1 g | — |
| Subject | Esomeprazole | Small molecule | 40 mg | — |
| Comparator | Tegoprazan | Other / unclassified | 50 mg | — |
| Comparator | Tripotassium dicitrate BM | Unknown | 300 mg | — |
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |